In the period from January to May 2025, sales of migraine medications in the Russian retail market reached 1.68 billion rubles, marking a 26.7% increase compared to the same period last year. According to the analytical company RNC Pharma, this uptick follows a two-year period of consistent decline in the physical volume of anti-migraine drug sales. In 2024, sales decreased by 1.2% compared to 2023, with a more significant drop of 3.9% in 2023 compared to 2022.
This decline in physical sales is attributed to overestimated figures during the spring of 2022, caused by heightened consumption during that period. Notably, ruble-based sales figures did not turn negative during these periods.
In fact, the current indicators reflect a return to pre-crisis levels, and the stabilization process, which started in 2024, allows us to speak of a rapid market recovery. In 2024, Russians purchased approximately 7.3 million packages of anti-migraine drugs worth 3.44 billion rubles.
Analysts note that the segment’s growth is mainly driven by increased demand for more expensive products. The natural market dynamics during this period showed only a modest growth of up to 1.7% in package volume, with inflation also contributing to the increase in ruble sales.
From January to May of 2025, unbranded products accounted for nearly 55% of the retail market for anti-migraine drugs. Despite an overall 3% decline in ruble sales of migraine drugs, a divergence has emerged: the generics segment is decreasing, while the market for sumatriptan-based drugs has increased by 22%. They now constitute nearly three-quarters of the total market—approximately 75% of all sales.
Of all the migraine medications, Adjovi, a drug produced by Teva Pharmaceutical, showed the greatest growth. Its sales increased threefold over the year. This is an all-time record for sales dynamics in rubles. Analysts added that Teva, with its Sumatriptan product, is a leader with 29% of the entire market.
The second-largest market share and growth rate belong to Exenza (Pharmamed), which tripled its sales. Kaporiza (Sotex) also experienced significant growth, increasing sales 2.2 times. Notably, Delmigren (Grotex) saw an extraordinary 8.6-fold increase in sales, setting a record growth rate, though it remains in 15th position by absolute sales volume.
Conversely, some medications saw declines: Migrepam (Binnopharm Group) lost 26% of its sales, and Amigrenin (Abbott) decreased by 12%.
